<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16481">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01706809</url>
  </required_header>
  <id_info>
    <org_study_id>S-20100006</org_study_id>
    <secondary_id>S-20100006</secondary_id>
    <nct_id>NCT01706809</nct_id>
  </id_info>
  <brief_title>Comparing of Different Biomarkers From Vena Rectalis Superior and Vena Cubiti in Patients Undergoing Low Anterior Resection for Rectum Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the present study is to investigate different biomarkers like VEGF, EVGF
      and others ability to predict time to recidive and progressions free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing LAR for rectum cancer is subjected. Preoperative blood samples from vena
      rectalis superior and vena cubiti is collected, as well as biopsies from tumor. Preoperative
      and after 3 month peripheral blood samples is collected.

      A total of 50 patients will be included in this study.

      The study is approved by the local scientific ethical committee No. S-20100006
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The primary aim of the present study is to investigate different biomarkers like VEGF, EVGF and others ability to predict time to recidive and progressions free survival.</measure>
    <time_frame>after the study is complete</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Biomarkeres</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sampels from vena rectalis superior and vena cubiti</intervention_name>
    <arm_group_label>Biomarkeres</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing open LAR for rectum cancer is subjected.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological verified cancer

          -  The cancer must be located in rectum maximum of 15 cm.

          -  Age above 18

        Exclusion Criteria:

          -  Disseminated cancer

          -  Perioperative radio-chemotherapy

          -  Laparoscopy surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vejle hospital</name>
      <address>
        <city>Vejle</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Rahr, MD</last_name>
      <phone>7940 5600</phone>
      <phone_ext>0045</phone_ext>
      <email>hans.rahr@slb.regionsyddanmark.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>October 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Mark Ellebaek Pedersen</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
